Although overall survival didn’t differ significantly between the study groups, the analysis was challenging by crossover from the placebo group to the lanreotide group and uncertainty over remedies after progression . Between-group differences with respect to quality of life weren’t significant . Among individuals with baseline degrees of chromogranin A that exceeded the higher limit of the normal range, the chances of at least a 50 percent reduction in these amounts were significantly greater with lanreotide than with placebo . Pharmacokinetic data are given in Table S5 in the Supplementary Appendix. Safety Similar proportions of patients in both groups had adverse events .). Most of these sufferers had mild events or moderate events . Half the sufferers in the lanreotide group experienced adverse events linked to the study medication , most commonly diarrhea .ACS recommends annual MRI screening in women with genealogy of breast cancer Women with a personal history of breast malignancy should consider annual screening with MRI in addition to mammography, according to a study presented today at the annual conference of the Radiological Culture of North America . The American Cancer Society guidelines currently suggest annual screening with breasts MRI in women with a known gene mutation or with a solid family history indicating an eternity threat of breast cancer higher than 20 %.